IPCA Laboratories Ltd
IPCALABIPCA Laboratories Ltd
IPCALABPrice Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
60.31 | 5.75 | 0.30% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.76 | 5.90 | 0.56% |
Forecast & Ratings
Detailed Forecastfrom 13 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Ipca Laboratories Limited is engaged in pharmaceuticals business. The Company is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs).
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 3,177.08 | 2,889.33 | 3,168.94 | 3,299.56 | 3,803.37 | 4,686.03 | 5,482.83 | 5,896.36 | 6,369.94 | 7,393.91 | ||||||||||
Raw Materials | 1,222.59 | 1,032.55 | 1,115.71 | 1,101.28 | 1,355.15 | 1,820.25 | 1,923.09 | 2,144.50 | 2,205.84 | 6,042.40 | ||||||||||
Power & Fuel Cost | 135.94 | 141.67 | 151.00 | 161.92 | 176.50 | 201.22 | 207.10 | 242.12 | 283.74 | |||||||||||
Employee Cost | 566.70 | 625.58 | 695.98 | 735.88 | 787.40 | 921.23 | 1,013.57 | 1,177.39 | 1,287.64 | |||||||||||
Selling & Administrative Expenses | 568.42 | 532.58 | 596.75 | 598.72 | 524.85 | 545.44 | 575.16 | 641.87 | 862.27 | |||||||||||
Operating & Other expenses | 110.67 | 242.49 | 147.58 | 205.93 | 208.35 | 228.73 | 153.49 | 311.14 | 675.41 | |||||||||||
EBITDA | 572.76 | 314.46 | 461.92 | 495.83 | 751.12 | 969.16 | 1,610.42 | 1,379.34 | 1,055.04 | 1,351.51 | ||||||||||
Depreciation/Amortization | 179.55 | 163.26 | 172.95 | 177.73 | 182.42 | 210.50 | 209.17 | 232.42 | 261.56 | 328.65 | ||||||||||
PBIT | 393.21 | 151.20 | 288.97 | 318.10 | 568.70 | 758.66 | 1,401.25 | 1,146.92 | 793.48 | 1,022.86 | ||||||||||
Interest & Other Items | 32.13 | 34.56 | 26.91 | 27.57 | 22.24 | 19.77 | 12.27 | 11.20 | 48.19 | 127.35 | ||||||||||
PBT | 361.08 | 116.64 | 262.06 | 290.53 | 546.46 | 738.89 | 1,388.98 | 1,135.72 | 745.29 | 895.51 | ||||||||||
Taxes & Other Items | 106.85 | 23.50 | 67.52 | 51.11 | 101.63 | 132.57 | 248.97 | 251.64 | 273.97 | 331.23 | ||||||||||
Net Income | 254.23 | 93.14 | 194.54 | 239.42 | 444.83 | 606.32 | 1,140.01 | 884.08 | 471.32 | 564.28 | ||||||||||
EPS | 13.43 | 3.69 | 7.71 | 12.65 | 35.23 | 47.99 | 59.99 | 34.85 | 18.58 | 22.24 | ||||||||||
DPS | 0.50 | 0.00 | 0.50 | 1.00 | 3.00 | 5.00 | 4.00 | 4.00 | 4.00 | 2.00 | ||||||||||
Payout ratio | 0.04 | 0.00 | 0.06 | 0.08 | 0.09 | 0.10 | 0.07 | 0.11 | 0.22 | 0.09 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
IPCA Laboratories Ltd | 72.21 | 5.75 | 0.30% |
Sun Pharmaceutical Industries Ltd | 43.54 | 6.22 | 0.75% |
Cipla Ltd | 39.63 | 4.68 | 0.62% |
Dr Reddy's Laboratories Ltd | 22.35 | 4.33 | 0.66% |
Price Comparison
Compare IPCALAB with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding IPCA Laboratories Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
HDFC MUTUAL FUND MID CAP OPP FUND DIRECT GROWTH OPEN ENDED Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 4.7121% | Percentage of the fund’s portfolio invested in the stock 2.66% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 9/71 (0) |
KOTAK EMERGING EQUITY SCHEME - DIRECT PLAN - GROWTH Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.5576% | Percentage of the fund’s portfolio invested in the stock 2.19% | Change in the portfolio weight of the stock over the last 3 months 0.16% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 10/90 (+2) |
DSP Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.0935% | Percentage of the fund’s portfolio invested in the stock 4.46% | Change in the portfolio weight of the stock over the last 3 months 0.64% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 2/61 (+3) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
IPCALAB has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.30%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.98 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateNov 22, 2023
Dividend/Share
₹2.00
Ex DateEx Date
Nov 22, 2023
Cash Dividend
Ex DateEx DateNov 22, 2022
Dividend/Share
₹4.00
Ex DateEx Date
Nov 22, 2022
Cash Dividend
Ex DateEx DateNov 22, 2021
Dividend/Share
₹8.00
Ex DateEx Date
Nov 22, 2021
Cash Dividend
Ex DateEx DateNov 13, 2020
Dividend/Share
₹8.00
Ex DateEx Date
Nov 13, 2020
Cash Dividend
Ex DateEx DateFeb 18, 2020
Dividend/Share
₹5.00
Ex DateEx Date
Feb 18, 2020
News & Opinions
Neutral IPCA Laboratories; target of Rs 860: Motilal Oswal
5 months ago•Moneycontrol
News Video
Ipca Labs Hits 52-Week High On Favourable US FDA Report For Its Ratlam Facility | CNBC TV18
5 months ago•CNBC-TV18
News Video
Stock Radar I IPCA Laboratories likely to top 1000 levels in the next 5-7 weeks: Shitij Gandhi
6 months ago•The Economic Times
Trade setup for Wednesday: Top 15 things to know before the opening bell
6 months ago•Moneycontrol
News Video
Laurus Labs, Syngene, Ipca, Gland Pharma Report Export Growth In August | BQ Prime
7 months ago•BQ Prime
Ipca Laboratories gains 3% on USFDA classification
7 months ago•Moneycontrol
Neutral Ipca Laboratories; target of Rs 840: Motilal Oswal
7 months ago•Moneycontrol
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 14.06%, vs industry avg of 8.36%
Increasing Market Share
Over the last 5 years, market share increased from 1.63% to 1.95%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 14.51%, vs industry avg of 9.82%